NCT06626464View on ClinicalTrials.gov

A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions

Healthy

Interventions

DRUG

[14C]MK-8189

Oral administration

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc. (Site 0001), Madison

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY